Market Research Industry Reports

Systemic Mastocytosis - Pipeline Review, H1 2018

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Systemic Mastocytosis - Pipeline Review, H1 2018

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Systemic Mastocytosis - Pipeline Review, H1 2018, provides an overview of the Systemic Mastocytosis (Gastrointestinal) pipeline landscape.

Systemic mastocytosis is a disorder where mast cells are abnormally increased in multiple organs including the bone marrow. Symptoms include shortness of breath, low blood pressure, hives and swelling, itching, diarrhea, headache, flushing and musculoskeletal pain. Treatment includes antihistamines and more aggressive forms of Systemic mastocytosis require interferon or chemotherapeutic agents.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Systemic Mastocytosis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Systemic Mastocytosis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Systemic Mastocytosis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Systemic Mastocytosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase II, Phase I and Preclinical stages are 1, 5, 3 and 1 respectively.

Systemic Mastocytosis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Systemic Mastocytosis (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Systemic Mastocytosis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Systemic Mastocytosis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Systemic Mastocytosis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Systemic Mastocytosis (Gastrointestinal)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Systemic Mastocytosis (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Systemic Mastocytosis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Systemic Mastocytosis - Overview 7
Systemic Mastocytosis - Therapeutics Development 8
Pipeline Overview 8
Pipeline by Companies 9
Products under Development by Companies 11
Systemic Mastocytosis - Therapeutics Assessment 12
Assessment by Target 12
Assessment by Mechanism of Action 14
Assessment by Route of Administration 16
Assessment by Molecule Type 18
Systemic Mastocytosis - Companies Involved in Therapeutics Development 20
AB Science SA 20
AbbVie Inc 20
Arog Pharmaceuticals Inc 21
Blueprint Medicines Corp 21
Bristol-Myers Squibb Co 22
Deciphera Pharmaceuticals LLC 22
Patara Pharma Inc 22
Seattle Genetics Inc 23
Stemline Therapeutics Inc 23
Systemic Mastocytosis - Drug Profiles 25
AK-002 - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
avapritinib - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
brentuximab vedotin - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
crenolanib besylate - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
cromolyn sodium - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
dasatinib - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
ibrutinib - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
masitinib - Drug Profile 107
Product Description 107
Mechanism Of Action 107
R&D Progress 107
ripretinib - Drug Profile 126
Product Description 126
Mechanism Of Action 126
R&D Progress 126
SL-401 - Drug Profile 130
Product Description 130
Mechanism Of Action 130
R&D Progress 130
Systemic Mastocytosis - Dormant Projects 138
Systemic Mastocytosis - Discontinued Products 139
Systemic Mastocytosis - Product Development Milestones 140
Featured News & Press Releases 140
Dec 10, 2017: Blueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of Avapritinib (BLU-285) in Patients with Advanced Systemic Mastocytosis Showing Evidence of Strong Clinical Activity 140
Dec 10, 2017: Blueprint Medicines: Rapid Responses, Few Adverse Effects Seen with Targeted Agent in Phase 1 Trial in Rare Blood Disorder 142
Nov 01, 2017: Blueprint Medicines Announces Publication of BLU-285 Translational Data 143
Nov 01, 2017: Blueprint Medicines to Present Updated Data from Ongoing Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Systemic Mastocytosis in Plenary Scientific Session at 59th ASH Annual Meeting and Exposition 143
Nov 01, 2017: Seattle Genetics to Present Data from Broad ADCETRIS (Brentuximab Vedotin) Development Program at ASH 2017 144
Aug 02, 2017: Blueprint Medicines Provides Update on Clinical Program of its Cancer Drug, BLU-285 146
Mar 27, 2017: Blueprint Medicines to Present on BLU-285 at Upcoming Scientific Conferences 147
Dec 04, 2016: Blueprint Medicines Announces Proof-of-Concept Data from Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Systemic Mastocytosis 147
Nov 03, 2016: Blueprint Medicines to Present Preliminary Data from Ongoing Phase 1 Clinical Trial for BLU-285 in Advanced Systemic Mastocytosis at 2016 ASH Annual Meeting 149
Oct 31, 2016: Deciphera Pharmaceuticals to Present Clinical Data on DCC-2618 at 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 150
Oct 28, 2016: Blueprint Medicines to Present Preclinical Data and Provide Enrollment Updates for Phase 1 Clinical Trial for BLU-285 in Advanced Systemic Mastocytosis at ECNM Annual Meeting 2016 150
Sep 15, 2016: Allakos Begins Clinical Trials of AK002 in Patients with Systemic Mastocytosis 151
Sep 10, 2015: Blueprint Medicines Receives FDA Authorization to Advance Novel Drug Candidate into Clinical Trial for Systemic Mastocytosis 151
Dec 08, 2014: Blueprint Medicines Debuts Comprehensive Preclinical Data Set on First Selective Drug for Patients with Systemic Mastocytosis at 2014 American Society of Hematology Annual Meeting 152
Dec 09, 2012: Seattle Genetics Highlights Adcetris Data In CD30-Positive Non-Hodgkin Lymphomas And Other Malignancies From Multiple Presentations At ASH Annual Meeting 153
Appendix 155
Methodology 155
Coverage 155
Secondary Research 155
Primary Research 155
Expert Panel Validation 155
Contact Us 155
Disclaimer 156

List Of Tables

List of Tables
Number of Products under Development for Systemic Mastocytosis, H1 2018 8
Number of Products under Development by Companies, H1 2018 10
Products under Development by Companies, H1 2018 11
Number of Products by Stage and Target, H1 2018 13
Number of Products by Stage and Mechanism of Action, H1 2018 15
Number of Products by Stage and Route of Administration, H1 2018 17
Number of Products by Stage and Molecule Type, H1 2018 19
Systemic Mastocytosis - Pipeline by AB Science SA, H1 2018 20
Systemic Mastocytosis - Pipeline by AbbVie Inc, H1 2018 21
Systemic Mastocytosis - Pipeline by Arog Pharmaceuticals Inc, H1 2018 21
Systemic Mastocytosis - Pipeline by Blueprint Medicines Corp, H1 2018 21
Systemic Mastocytosis - Pipeline by Bristol-Myers Squibb Co, H1 2018 22
Systemic Mastocytosis - Pipeline by Deciphera Pharmaceuticals LLC, H1 2018 22
Systemic Mastocytosis - Pipeline by Patara Pharma Inc, H1 2018 23
Systemic Mastocytosis - Pipeline by Seattle Genetics Inc, H1 2018 23
Systemic Mastocytosis - Pipeline by Stemline Therapeutics Inc, H1 2018 24
Systemic Mastocytosis - Dormant Projects, H1 2018 138
Systemic Mastocytosis - Discontinued Products, H1 2018 139

List Of Figures

List of Figures
Number of Products under Development for Systemic Mastocytosis, H1 2018 8
Number of Products under Development by Companies, H1 2018 9
Number of Products by Top 10 Targets, H1 2018 12
Number of Products by Stage and Top 10 Targets, H1 2018 12
Number of Products by Top 10 Mechanism of Actions, H1 2018 14
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018 14
Number of Products by Routes of Administration, H1 2018 16
Number of Products by Stage and Routes of Administration, H1 2018 16
Number of Products by Molecule Types, H1 2018 18
Number of Products by Stage and Molecule Types, H1 2018 18

Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2018

Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2018The latest Pharmaceutical and Healthcare disease pipeline guide Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2018, provides an overview of the Systemic Sclerosis

USD 2000View Report

Systemic Lupus Erythematosus - Pipeline Review, H1 2018

Systemic Lupus Erythematosus - Pipeline Review, H1 2018Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Systemic Lupus Erythematosus - Pipeline Review, H1 2018, provides an overview of the

USD 2000View Report

Systemic Mastocytosis - Market Insight, Epidemiology and Market Forecast - 2027

DelveInsights Systemic Mastocytosis - Market Insight, Epidemiology and Market Forecast - 2027 report provides a detailed analysis of the Systemic Mastocytosis epidemiology and market outlook for the 7MM.Markets

USD 6250View Report

Systemic Mastocytosis - Epidemiology Forecast to 2027

DelveInsights Systemic Mastocytosis - Epidemiology Forecast, 2027 report provides a comprehensive analysis of the Systemic Mastocytosis epidemiology, providing the historical and forecasted data for the 7MM

USD 3250View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 2000
  • Site Licence    USD 4000
  • Enterprise Wide Licence    USD 6000
$ 2000

Reports Details

Published Date : May 2018
No. of Pages :156
Country :Global
Category :Pharmaceuticals and Healthcare
Publisher :Global Markets Direct
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube